MICU Vicuron Pharmaceuticals (MM)

Vicuron Pharmaceuticals to Present at the Wells Fargo Securities Health Care Fireside Chats in New York KING OF PRUSSIA, Pa., March 18 /PRNewswire-FirstCall/ -- Vicuron Pharmaceuticals Inc. today announced that Dov A. Goldstein, M.D., Executive Vice President, is scheduled to present a corporate and product update at the Wells Fargo Securities Health Care Fireside Chats on Wednesday, March 24, 2004. Dr. Goldstein will give the update at 11:15 AM Eastern Time. To access the live audio broadcast or the subsequent archived recording log on to http://www.vicuron.com/ and click on the investor relations section. Please connect to the website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary. The live broadcast will be archived for 30 days. About Vicuron Vicuron Pharmaceuticals is an international biopharmaceutical company focused on discovering, developing, manufacturing and commercializing vital medicine for seriously ill patients. The company's lead products are in Phase III clinical trials include anidulafungin, a novel antifungal agent, and dalbavancin, a novel intravenous antibiotic for the treatment of serious Gram-positive infections. Vicuron's versatile researchengine integrates industry-leading expertise in functional genomics, natural products discovery, mechanism-based drug design and combinatorial and medicinal chemistry. These approaches are yielding promising novel and next-generation compounds, many ofwhich are in the later stages of preclinical development. In addition, Vicuron has research and development collaborations with leading pharmaceutical companies, such as Pharmacia Corporation and Novartis, and fully owns BIMA, a manufacturing subsidiary. DATASOURCE: Vicuron Pharmaceuticals Inc. CONTACT: Dov A. Goldstein, M.D. of Vicuron Pharmaceuticals, +1-610-205-2312, ; or E. Blair Schoeb of Burns McClellan, +1-212-213-0006, , for Vicuron Pharmaceuticals Inc.; or Ian R. McConnell of WeissCom Partners, +1-415-362-5018, Web site: http://www.vicuron.com/

Copyright